Skip to main content
OpenTrials

Clinical trial condition

Fallopian Tube Diseases

Explore clinical trials studying Fallopian Tube Diseases. Study availability and eligibility vary by location and protocol.

598 public trials 89 recruiting studies
Refine in advanced search Browse all conditions

Fallopian Tube Diseases trial results

Active, Not Recruiting

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +15 more
Locations
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Arizona Center for Cancer Care (ACCC) - Biltmore Scottsdale, Arizona, United States
  • University of Arizona Cancer Center - Research and Administration at Main Campus Tucson, Arizona, United States
  • Providence Saint Joseph Medical Center - Roy and Patricia Disney Family Cancer Center Burbank, California, United States
View all 177 locations
View Trial Details
Active, Not Recruiting

Testing the Use of A Single Drug (Olaparib) or the Combination of Two Drugs (Cediranib and Olaparib) Compared to the Usual Chemotherapy for Women With Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

NCT02446600

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +27 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • University of South Alabama Mitchell Cancer Institute Mobile, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
View all 356 locations
View Trial Details
Active, Not Recruiting

Testing the Combination of Cediranib and Olaparib in Comparison to Each Drug Alone or Other Chemotherapy in Recurrent Platinum-Resistant Ovarian Cancer

NCT02502266

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +29 more
Locations
  • University of Alabama at Birmingham Cancer Center Birmingham, Alabama, United States
  • Alaska Women's Cancer Care Anchorage, Alaska, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
View all 398 locations
View Trial Details
Active, Not Recruiting

Carboplatin, Gemcitabine Hydrochloride, and Berzosertib in Treating Patients With Recurrent and Metastatic Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02627443

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +26 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • UF Health Cancer Institute - Gainesville Gainesville, Florida, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

A Study of Olaparib Prior to Surgery and Chemotherapy in Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

NCT02489006

Conditions
Adnexal Diseases, Debulking Surgical Procedures, Endocrine Gland Neoplasms, +18 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • Ottawa Regional Cancer Centre Ottawa, Ontario, Canada
  • Princess Margaret Cancer Centre Toronto, Ontario, Canada
  • Centre hospitalier de l'Université de Montréal (CHUM Montreal, Quebec, Canada
View Trial Details
Active, Not Recruiting

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947

Conditions
Adenocarcinoma, Adnexal Diseases, Bladder Cancer, +58 more
Locations
  • HonorHealth Research Institute Scottsdale, Arizona, United States
  • AOA-HOPE Tucson, Arizona, United States
  • USC Norris Comprehensive Cancer Center Los Angeles, California, United States
  • HOAG Memorial Hospital Presbyterian Newport, California, United States
View all 14 locations
View Trial Details
Active, Not Recruiting

Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer

NCT04034927

Conditions
Adnexal Diseases, Fallopian Tube Diseases, Fallopian Tube Endometrioid Tumor, +23 more
Locations
  • UC Irvine Health/Chao Family Comprehensive Cancer Center Orange, California, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Hartford Hospital Hartford, Connecticut, United States
  • Augusta University Medical Center Augusta, Georgia, United States
View all 20 locations
View Trial Details
Active, Not Recruiting

Gemcitabine Hydrochloride Alone or With M6620 in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT02595892

Conditions
Adnexal Diseases, Endocrine Gland Neoplasms, Endocrine System Diseases, +18 more
Locations
  • Mayo Clinic Hospital in Arizona Phoenix, Arizona, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • UC San Diego Medical Center - Hillcrest San Diego, California, United States
View all 17 locations
View Trial Details

Related conditions